Harvard Bioscience Subsidiary Data Sciences International Launches Digital Telemetry Implant for Measuring Respiratory Endpoi...
May 15 2019 - 4:00PM
Data Sciences International (DSI), a subsidiary of Harvard
Bioscience, Inc. (Nasdaq: HBIO) and the global leader in wireless
physiologic monitoring, will showcase its new PhysioTel™ Digital
L11R cardiopulmonary implant at the American Thoracic Society
Meeting in Dallas on May 19-21.
Launched in April 2019, this is the final upgrade from the
legacy large animal platform to PhysioTel Digital. The PhysioTel
Digital L11R replaces the D70-PCTR, the original cardiopulmonary
implant. The L11R maintains the versatility of its predecessor by
monitoring pressure, biopotential, temperature, respiratory volume,
respiratory rate and activity while incorporating enhancements from
the PhysioTel Digital platform. These enhancements include:
- Social housing compatibility with a wide range of
enclosures
- Automated configuration eliminates human errors and provides a
fast study start-up
- Encoded animal ID ensures traceability and GLP compliance
- Remote programming for convenient, safe and easy device battery
management
The L11R allows safety pharmacology clients to combine
previously separate cardiovascular and respiratory studies.
Eliminating the additional study saves clients time and money while
reducing the number of animals required. In addition, biodefense
researchers may use the L11R for both dosimetry and improved
disease state monitoring. Combining respiratory and cardiovascular
endpoints results in a more accurate assessment of dosing and
disease course. This enables better translation to clinical
benefits in humans, thus faster FDA approval through the Animal
Rule.
“The trend among researchers is to collect as much information
in as few studies as possible,” said Jeff Duchemin, President and
CEO of Harvard Bioscience. “Our customers have asked for an implant
capable of simultaneously collecting cardiovascular and respiratory
endpoints for the PhysioTel Digital platform. We are confident this
implant will reinforce DSI’s position as the industry leader.”
About Data Sciences International
Data Sciences International (DSI) provides a complete
preclinical platform to assess physiological data for research
ranging from basic, to drug discovery, and drug development. DSI is
the leading provider of telemetry systems, pulmonary solutions,
associated software platforms, and services. DSI is a subsidiary of
Harvard Bioscience (Nasdaq: HBIO) a global developer, manufacturer,
and marketer of a broad range of specialized products for life
science research.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and
marketer of a broad range of solutions to advance life science. Our
products are sold to thousands of researchers in over 100 countries
through our global sales organization, websites, catalogs, and
through distributors including Thermo Fisher Scientific Inc., VWR,
GE Healthcare, and other specialized distributors. We have sales
and manufacturing operations in the United States, the United
Kingdom, Germany, Sweden, Spain, France, Canada and China. For more
information, please visit our website at
www.harvardbioscience.com.
Contact:Corey ManchesterCorporate ControllerTel: 508 893
8999
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From May 2023 to May 2024